Literature DB >> 25331590

Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells.

Asli Ekin1, Omer Faruk Karatas, Mustafa Culha, Mustafa Ozen.   

Abstract

BACKGROUND: Cancer is one of the most common causes of human deaths worldwide. Nanotechnology has the potential to facilitate the detection, diagnosis, and treatment of cancer cases. Successful delivery of nucleic acids into cancer cells with the use of nanoparticles would be a significant improvement for medical and cellular biology. The use of nanoparticle-based vehicles in clinical treatment is considerably important for treating genetic disorders. Gold nanoparticles (AuNPs) have been suggested as therapeutic delivery tools for cancer. Because microRNAs (miRNAs), which induce post-transcriptional gene silencing, are deregulated in cancer cells, they are also considered as strong candidates for cancer therapy applications. In prostate and breast cancer, miR-145, a well-known tumor suppressor miRNA, is strongly downregulated in tumor tissues compared to their corresponding normal tissues.
METHODS: In the present study, we aimed to use engineered AuNPs as nanocarrier platforms to deliver miRNAs to prostate/breast cancer cells. 13-nm AuNPs were modified with thiolated RNAs and then the miR-145 was hybridized to the RNAs that were chemically attached to the AuNPs.
RESULTS: The results obtained in the present study demonstrate the efficient delivery of miR-145 to prostate/breast cancer cells. We also show that delivery was more efficient when the AuNP-RNA-miRNA carrier complex was formed at an elevated temperature of 72 °C.
CONCLUSIONS: In conclusion, we show that AuNPs help the effective in vitro delivery of miR-145 into cancer cells.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  gold nanoparticle; hybridization; microRNA; mir-145; oligonucleotide

Mesh:

Substances:

Year:  2014        PMID: 25331590     DOI: 10.1002/jgm.2810

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  29 in total

Review 1.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 2.  Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells.

Authors:  Kirti S Prabhu; Afsheen Raza; Thasni Karedath; Syed Shadab Raza; Hamna Fathima; Eiman I Ahmed; Shilpa Kuttikrishnan; Lubna Therachiyil; Michal Kulinski; Said Dermime; Kulsoom Junejo; Martin Steinhoff; Shahab Uddin
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

Review 3.  Non-viral based miR delivery and recent developments.

Authors:  Annalise Elizabeth Labatut; George Mattheolabakis
Journal:  Eur J Pharm Biopharm       Date:  2018-04-19       Impact factor: 5.571

Review 4.  MicroRNA Therapeutics: the Next Magic Bullet?

Authors:  Bridget Simonson; Saumya Das
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

Review 5.  Smart nanomaterials for cancer diagnosis and treatment.

Authors:  Ragini Singh; Ayush Sharma; Joel Saji; Akhela Umapathi; Santosh Kumar; Hemant Kumar Daima
Journal:  Nano Converg       Date:  2022-05-15

Review 6.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

Review 7.  Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.

Authors:  Michael-Joseph Gorbet; Ashish Ranjan
Journal:  Pharmacol Ther       Date:  2019-12-19       Impact factor: 12.310

Review 8.  Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments.

Authors:  Johan Karlsson; Hannah J Vaughan; Jordan J Green
Journal:  Annu Rev Chem Biomol Eng       Date:  2018-03-26       Impact factor: 11.059

9.  CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis.

Authors:  Ozel Capik; Fatma Sanli; Ali Kurt; Onur Ceylan; Ilknur Suer; Murat Kaya; Michael Ittmann; Omer Faruk Karatas
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-03-22       Impact factor: 5.554

Review 10.  In vivo methods for acute modulation of gene expression in the central nervous system.

Authors:  Andrzej W Cwetsch; Bruno Pinto; Annalisa Savardi; Laura Cancedda
Journal:  Prog Neurobiol       Date:  2018-04-22       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.